Retrospective Cohort Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2017; 23(3): 464-471
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.464
Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients
Mark Prince, Lynn Lester, Rupal Chiniwala, Barry Berger
Mark Prince, USMD Health System, Arlington, TX 76017, United States
Lynn Lester, USMD Health System, Fort Worth, TX 76104, United States
Rupal Chiniwala, USMD Health System, Irving Texas, TX 75039, United States
Barry Berger, Exact Sciences Corporation, Madison, WI 53729, United States
Author contributions: Prince M, Lester L and Berger B contributed to study concept and design; Prince M, Lester L, Chiniwala R and Berger B contributed to data acquisition; Prince M and Berger B contributed to analysis, interpretation and manuscript drafting and revision; Prince M, Lester L, Chiniwala R and Berger B contributed to critical revision for intellectual content; Prince M and Berger B contributed to statistical analysis; Prince M and Lester L contributed to clinical study supervision and clinical data acquisition; Berger B contributed to laboratory data acquisition and histopathologic report analysis.
Institutional review board statement: This cohort study was performed under the peer-reviewed quality assurance guidelines involving only retrospective records review by the medical institutions involved in the care of patients and was waived for IRB review.
Conflict-of-interest statement: Mark Prince, Lynn Lester, and Rupal Chiniwala have no conflict of interest related to the manuscript. Barry Berger is an employee and owns stock in Exact Sciences Corporation.
Data sharing statement: De-identified medical records have been archived for review at USMD by Mark Prince, MD, MBA, AGAF Director of Gastroenterology USMD Health System, 801 W Interstate 20, Ste 132, Arlington, TX 76017, United States.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Barry Berger, MD, Exact Sciences Corporation, 441 Charmany Drive, Madison, WI 53719, United States. bberger@exactsciences.com
Telephone: +1-617-2937738
Received: October 13, 2016
Peer-review started: October 14, 2016
First decision: November 21, 2016
Revised: December 10, 2016
Accepted: December 21, 2016
Article in press: December 21, 2016
Published online: January 21, 2017
Processing time: 93 Days and 4.1 Hours
Core Tip

Core tip: The availability of multitarget stool DNA (mt-sDNA) colorectal cancer screening led to high screening compliance (88%) and diagnostic colonoscopy compliance on mt-sDNA positive cases (96%) in a cohort of previously screening non-compliant Medicare patients ages 50-85 years in a multi-specialty group practice setting.